Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 6—June 2011

Research

Use of Antiviral Drugs to Reduce Household Transmission of Pandemic (H1N1) 2009, United Kingdom1

Richard G. PebodyComments to Author , Ross Harris, George Kafatos, Mary Chamberland, Colin Campbell, Jonathan S. Nguyen-Van-Tam, Estelle McLean, Nick Andrews, Peter J. White, Edward Wynne-Evans, Jon Green, Joanna Ellis, Tim Wreghitt, Sam Bracebridge, Chikwe Ihekweazu, Isabel Oliver, Gillian Smith, Colin Hawkins, Roland Salmon, Brian Smyth, Jim McMenamin, Maria Zambon, Nick F. Phin, and John M. Watson
Author affiliations: Author affiliations: Health Protection Agency, London, UK (R.G. Pebody, R. Harris, G. Kafatos, M. Chamberland, C. Campbell, J.S. Nguyen-Van-Tam, E. McLean, N. Andrews, P.J. White, E. Wynne-Evans, J. Green, J. Ellis, T. Wreghitt, S. Bracebridge, C. Ihekweazu, I. Oliver, G. Smith, C. Hawkins, M. Zambon, N. Phin, J.M. Watson); Imperial College, London (P.J. White); Public Health Wales, Cardiff, Wales, UK (R. Salmon); Public Health Agency Northern Ireland, Belfast, Northern Ireland (B. Smyth); Health Protection Scotland, Glasgow, Scotland (J. McMenamin)

Main Article

Table 7

Univariate and multivariate analysis of pandemic (H1N1) 2009 SAR infection for acute respiratory infection, by gender, age group and prophylaxis, United Kingdom, 2009*

Variable
No. contacts†
No. secondary
case-patients
Univariate analysis
Multivariate analysis
SAR, % (95% CI)
p value‡
OR (95% CI)
p value
Sex, n = 704
M 339 56 16.5 (12.9–20.9) 1.0, baseline
F
365
64
17.5 (12.5–24)
0.72

1.9 (1.0–3.5)
0.04
Age, y
<16 194 49 25.3 (15.4–38.6) 7.0 (3.0–21.0)
16–49 359 56 15.6 (9.2–25.2) 3.6 (1.5–8.8)
>50
166
15
9.0 (5.5–14.4)
<0.001

1.0, baseline
0.001
Prophylaxis, n = 549
No 106 80 75.5 (66.4–82.7) 1, baseline
Yes
443
34
7.7 (4.5–12.7)
<0.001

0.02 (0.01–0.03)
<0.001
Primary case-patient treatment
>48 h 435 79 18.2 (14.8–22.1) 1, baseline
<48 h
284
41
14.4 (10.1–20.3)
0.019

1.7 (0.9–3.1)
0.11
Total 719 120 16.7 (14.1–19.6)

*n = 719 except as indicated. Hosmer-Lemeshow goodness-of-fit test for multivariate model, p = 0.392. SAR, secondary attack rate; CI, confidence interval; OR, odds ratio.
†Excludes coprimary case-patients.
‡Indicates overall p-value for differences by group.

Main Article

1Elements of this work were presented at the Health Protection Agency Annual Conference in 2009. An abstract was presented at the International Conference on Emerging Infectious Diseases, Atlanta, Georgia, USA, 2010.

TOP